[TTF-1-negative lung adenocarcinoma: special features of systemic treatment]

Area of Science:

• Oncology
• Medical Oncology
• Thoracic Oncology

Background:

• Biomarker-adjusted treatments, including checkpoint inhibitors (CPI), have transformed metastatic lung cancer care.
• Programmed death ligand 1 (PD-L1) expression correlates with CPI efficacy, guiding treatment decisions.
• Immunochemotherapy is standard for PD-L1 <50%, with chemotherapy backbone importance increasing as PD-L1 expression decreases.

Purpose of the Study:

• To evaluate the efficacy of different chemotherapy backbones in lung adenocarcinoma patients treated with immunochemotherapy.
• To investigate the role of thyroid transcription factor 1 (TTF-1) status in determining optimal chemotherapy choice.

Main Methods:

• Review of retrospective data comparing pemetrexed- and taxane-based regimens.
• Initiation of a prospective randomized clinical trial to confirm findings.

Main Results:

• Retrospective analyses suggest taxane-based regimens may provide superior survival outcomes.
• This potential benefit appears more pronounced in patients negative for thyroid transcription factor 1 (TTF-1).

Conclusions:

• Taxane-based chemotherapy may be a preferred option for TTF-1 negative lung adenocarcinoma patients receiving immunochemotherapy.
• Prospective trials are crucial to validate these retrospective findings and optimize treatment selection.